Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00250575
Status:
COMPLETED
Last Update Posted:
2016-04-21
First Post:
2005-11-07
Brief Title:
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 24-week Multicenter Open-label Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clozapine is an antipsychotic This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia
This study is not recruiting in the United States
This study is not recruiting in the United States
Detailed Description:
Clozapine is an antipsychotic This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None